{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+Intravenous+%28Human%29&page=6", "query": { "intervention": "Immune Globulin Intravenous (Human)", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 461, "total_pages": 47, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+Intravenous+%28Human%29&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Immune+Globulin+Intravenous+%28Human%29&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T20:35:29.399Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01594437", "title": "Safety Study of Human Anti-Cytomegalovirus Monoclonal Antibody", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cytomegalovirus Infections" ], "interventions": [ { "name": "TCN-202", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Theraclone Sciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 48, "start_date": "2012-05", "completion_date": "2013-03", "has_results": false, "last_update_posted_date": "2014-03-21", "last_synced_at": "2026-10-14T20:35:29.399Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01594437" }, { "nct_id": "NCT06795022", "title": "First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "AZD9793 Intravenous (IV) monotherapy", "type": "DRUG" }, { "name": "AZD9793 Subcutaneous (SC) monotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 304, "start_date": "2025-03-27", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-10-14", "last_synced_at": "2026-10-14T20:35:29.399Z", "location_count": 7, "location_summary": "La Jolla, California • Los Angeles, California • Baltimore, Maryland + 4 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT06795022" }, { "nct_id": "NCT06345001", "title": "A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hepatocellular Carcinoma (HCC)", "Solid Tumors" ], "interventions": [ { "name": "BAY3630942", "type": "DRUG" }, { "name": "BAY3547922", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2024-08-26", "completion_date": "2025-03-31", "has_results": false, "last_update_posted_date": "2025-04-13", "last_synced_at": "2026-10-14T20:35:29.399Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Duarte, California • Los Angeles, California + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06345001" }, { "nct_id": "NCT06594068", "title": "Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "Anifrolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 16, "start_date": "2026-01-16", "completion_date": "2027-08-31", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-14T20:35:29.399Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT06594068" }, { "nct_id": "NCT00110708", "title": "Safety and Efficacy Study in the Treatment of Intestinal Problems Associated With Autism", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Autism", "Autistic Disorder", "Child Development Disorders, Pervasive", "Gastrointestinal Diseases", "Signs and Symptoms, Digestive" ], "interventions": [ { "name": "Oralgam (human immunoglobulin)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "PediaMed Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Years to 18 Years" }, "enrollment_count": 120, "start_date": "2005-04", "completion_date": "2006-06", "has_results": false, "last_update_posted_date": "2006-02-22", "last_synced_at": "2026-10-14T20:35:29.399Z", "location_count": 22, "location_summary": "Phoenix, Arizona • Sacramento, California • Gainesville, Florida + 17 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Sacramento", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00110708" }, { "nct_id": "NCT01804829", "title": "Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Infection", "Viruses", "Hepatocellular Carcinoma", "Hepatitis, Viral, Human", "Liver Cirrhosis" ], "interventions": [ { "name": "Civacir® 10%", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Biotest Pharmaceuticals Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 80, "start_date": "2013-06", "completion_date": "2016-06", "has_results": false, "last_update_posted_date": "2017-03-15", "last_synced_at": "2026-10-14T20:35:29.399Z", "location_count": 23, "location_summary": "Los Angeles, California • San Francisco, California • Miami, Florida + 15 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01804829" }, { "nct_id": "NCT02956746", "title": "A Comparison of the Safety, PD and PK of a Single Dose of SYN023 Administered With Licensed Rabies Vaccines", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Human Rabies" ], "interventions": [ { "name": "SYN023", "type": "BIOLOGICAL" }, { "name": "Imovax", "type": "BIOLOGICAL" }, { "name": "RabAvert", "type": "BIOLOGICAL" }, { "name": "HyperRAB ST (human rabies immune globulin)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Synermore Biologics Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 164, "start_date": "2016-08", "completion_date": "2018-01", "has_results": true, "last_update_posted_date": "2019-02-27", "last_synced_at": "2026-10-14T20:35:29.399Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02956746" }, { "nct_id": "NCT04736173", "title": "Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Nonsquamous Non Small Cell Lung Cancer", "Squamous Non Small Cell Lung Cancer", "Lung Cancer" ], "interventions": [ { "name": "Domvanalimab", "type": "DRUG" }, { "name": "Zimberelimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arcus Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 169, "start_date": "2021-02-08", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-14T20:35:29.399Z", "location_count": 3, "location_summary": "Columbus, Georgia • Kingwood, Texas • Blacksburg, Virginia", "locations": [ { "city": "Columbus", "state": "Georgia" }, { "city": "Kingwood", "state": "Texas" }, { "city": "Blacksburg", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04736173" }, { "nct_id": "NCT00814320", "title": "Gammagard Liquid and rHuPH20 in PID", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Primary Immunodeficiency Diseases (PID)" ], "interventions": [ { "name": "Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Baxalta now part of Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 89, "start_date": "2008-12-18", "completion_date": "2010-11-11", "has_results": true, "last_update_posted_date": "2021-05-19", "last_synced_at": "2026-10-14T20:35:29.399Z", "location_count": 13, "location_summary": "Cypress, California • Irvine, California • Los Angeles, California + 10 more", "locations": [ { "city": "Cypress", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Centennial", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00814320" }, { "nct_id": "NCT03952637", "title": "A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lysosomal Diseases", "Gangliosidosis", "GM1" ], "interventions": [ { "name": "AAV9-GLB1", "type": "BIOLOGICAL" }, { "name": "Abdominal ultrasound", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Audiology assessment with ABR", "type": "DIAGNOSTIC_TEST" }, { "name": "Bone density scan (DEXA)", "type": "DIAGNOSTIC_TEST" }, { "name": "Electrocardiogram (EKG)", "type": "DIAGNOSTIC_TEST" }, { "name": "Echocardiogram", "type": "DIAGNOSTIC_TEST" }, { "name": "Electroencephalogram (EEG) awake and extended overnight", "type": "OTHER" }, { "name": "Laboratory tests", "type": "DIAGNOSTIC_TEST" }, { "name": "Lumbar puncture", "type": "PROCEDURE" }, { "name": "Brain MRI/MRS/fMRI", "type": "PROCEDURE" }, { "name": "Neurocognitive testing", "type": "BEHAVIORAL" }, { "name": "Neurology exam", "type": "OTHER" }, { "name": "PICC or other Central line placement", "type": "BEHAVIORAL" }, { "name": "Skeletal survey", "type": "PROCEDURE" }, { "name": "Skin biopsy", "type": "PROCEDURE" }, { "name": "Speech and modified barium swallow study", "type": "PROCEDURE" }, { "name": "Ophthalmology exam", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "DIAGNOSTIC_TEST", "OTHER", "BEHAVIORAL" ], "sponsor": "National Human Genome Research Institute (NHGRI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "12 Years", "sex": "ALL", "summary": "6 Months to 12 Years" }, "enrollment_count": 54, "start_date": "2019-08-19", "completion_date": "2030-01-01", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-14T20:35:29.399Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03952637" } ] }